Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On March 9, 2017, Blueprint Medicines Corporation (the Company)
announced its financial results for the quarter and year ended
December 31, 2016. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference
herein.

The information in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is intended to be furnished and
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such
filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 of this Current
Report on Form 8-Kshall be deemed to be furnishedand not filed:

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Blueprint Medicines Corporation (NASDAQ:BPMC) Recent Trading Information

Blueprint Medicines Corporation (NASDAQ:BPMC) closed its last trading session up +0.53 at 34.79 with 206,738 shares trading hands.